Acorda Therapeutics Announces GGF2 Preclinical Data on Treatment of Erectile Dysfunction
Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced data from a
preclinical study showed that treatment with Glial Growth Factor 2
(GGF2) improved erectile function in an animal model following a
cavernous nerve (CN) injury, a common complication of prostate surgery.
These data were featured in a platform presentation at the ISSM/SMSNA
World Meeting on Sexual Medicine in Chicago, IL.
Approximately 270,000 prostate surgeries are performed in the United
States annually. The vast majority of those surgeries are to treat
prostate cancer and prostate enlargement (benign prostatic hyperplasia,
or BPH). The National Cancer Institute estimates that approximately
120,000 men in the U.S. diagnosed with prostate cancer in 2012 will have
surgery to remove the prostate. The American